Uncategorized files

Showing below up to 50 results in range #23,371 to #23,420.

• 
  EwingSarcomaTibia.jpg 256 × 686; 9 KB
  
• 
  Ewing Sarcoma Skeletal.jpg 630 × 630; 197 KB
  
• 
  Ewings-sarcoma-101.jpg 488 × 599; 13 KB
  
• 
  Ewings sarcoma histology.jpg 640 × 427; 117 KB
  
• 
  Ewings sarcoma histology 2.jpg 640 × 427; 142 KB
  
• 
  ExAntiseptic.jpg 202 × 147; 22 KB
  
• 
  Examination of a X-Ray exposure.jpg 448 × 294; 17 KB
  
• 
  Example.jpg 416 × 495; 122 KB
  
• 
  Example1.jpg 396 × 85; 25 KB
  
• 
  Example2.jpg 361 × 146; 10 KB
  
• 
  Example3.jpg 150 × 150; 1 KB
  
• 
  Example4.jpg 333 × 277; 20 KB
  
• 
  Example43.png 50 × 50; 4 KB
  
• 
  Example of QTL-Scan on a single Chromosom from PLoS Biology.jpg 563 × 600; 19 KB
  
• 
  Example of a Genome-wide QTL-Scan from PLoS Biology.jpg 800 × 573; 78 KB
  
• 
  Excel Model for TWA analysis.xls ; 9.35 MB
  
• 
  Excision Preauricular Cyst 200SQ.jpg 200 × 200; 58 KB
  
• 
  Excitation Contraction Coupling.png 657 × 485; 139 KB
  
• 
  Exelon NDC 00780323.jpg 640 × 480; 99 KB
  
• 
  Exelon NDC 00780324.jpg 1,024 × 781; 151 KB
  
• 
  Exelon NDC 00780325.jpg 640 × 480; 114 KB
  
• 
  Exelon NDC 00780326.jpg 640 × 480; 120 KB
  
• 
  Exemestane.svg 740 × 600; 19 KB
  
• 
  Exemestane 25 mg.png 542 × 303; 127 KB
  
• 
  Exemestane Adjuvant Treatment in Early Breast Cancer.png 587 × 2,496; 246 KB
  
• 
  Exemestane Adverse Reactions Advanced Breast Cancer.png 581 × 1,122; 89 KB
  
• 
  Exemestane Chemical structure.png 218 × 203; 13 KB
  
• 
  Exemestane Demographics and Baseline Characteristics from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy.png 587 × 991; 116 KB
  
• 
  Exemestane Efficacy Results from the Comparative Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Tamoxifen Therapy.png 588 × 508; 62 KB
  
• 
  Exemestane Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer.png 631 × 990; 143 KB
  
• 
  Exemestane FDA package label.png 616 × 1,487; 126 KB
  
• 
  Exemestane Incidence of Adverse Events of all Grades and Illnesses.png 587 × 1,006; 88 KB
  
• 
  Exemestane Incidence of Selected Treatment-Emergent Adverse Events.png 584 × 736; 61 KB
  
• 
  Exemestane Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control.png 586 × 238; 23 KB
  
• 
  Exemestane Primary Endpoint Events.png 586 × 447; 45 KB
  
• 
  Exemestane Time to Tumor Progression.png 637 × 355; 83 KB
  
• 
  Exemestane structure.png 262 × 357; 30 KB
  
• 
  Exenatide PD 01.png 1,126 × 523; 136 KB
  
• 
  Exenatide PD 02.png 1,208 × 386; 91 KB
  
• 
  Exenatide PD 03.png 1,156 × 668; 133 KB
  
• 
  Exenatide adverse 01.png 1,190 × 491; 114 KB
  
• 
  Exenatide adverse 02.png 944 × 131; 28 KB
  
• 
  Exenatide adverse 03.png 940 × 234; 41 KB
  
• 
  Exenatide adverse 04.png 940 × 167; 35 KB
  
• 
  Exenatide adverse 05.png 942 × 248; 44 KB
  
• 
  Exenatide clinical studies 01.png 1,116 × 458; 103 KB
  
• 
  Exenatide clinical studies 02.png 1,209 × 652; 145 KB
  
• 
  Exenatide clinical studies 03.png 1,210 × 251; 68 KB
  
• 
  Exenatide clinical studies 04.png 961 × 326; 80 KB
  
• 
  Exenatide clinical studies 05.png 959 × 192; 37 KB